Helsinki-based VC firm Voima Ventures has appointed Stina Wallmark as its new Life Sciences Investment Director, a move that aims to bolster the company’s expertise in biotech and healthcare across the Nordics and Baltics. Wallmark brings 15 years of experience in the life sciences sector. In her new role, she will focus on identifying promising startups in the life sciences field, particularly in areas such as synthetic biology, precision therapies, and AI-driven diagnostics. Her appointment highlights Voima’s growing commitment to supporting innovations that address critical global health challenges, including aging populations and the need for advanced healthcare solutions.
Voima Ventures is a venture capital firm that focuses on supporting deep technology startups, particularly those developing innovative solutions in fields like biotech, AI, and synthetic biology. The firm works with founders who are committed to creating technologies that may take time to mature but have the potential to drive significant global change. Voima’s approach combines the scientific rigor of innovation with the experience of Nordic entrepreneurs who have successfully built and scaled businesses. With a broad, global perspective, Voima Ventures helps guide these startups as they navigate the complex journey from early-stage development to broader market adoption.
Stina brings a wealth of knowledge from her career, including 15 years in various operational roles in the Life Sciences and Healthcare industry with GE Healthcare and Cytiva. As an Investment Manager at Almi Invest for the last three years, she has worked on building startups and scaleups with cutting-edge biotech solutions, positioning her as a key figure in identifying promising startups in the life sciences field across the Nordic and Baltics. Based in Sweden, Stina will help drive Voima Venture’s focus on emerging technologies that address global health and societal challenges across the Nordics and Baltics.
“At Voima Ventures, our mission is to scale solutions that benefit people, the planet, and industries,” says Inka Mero, Voima Ventures’ Founder and Managing Partner. “As a leader in European deep tech VC, we prioritise diversity and impact within our team and across our portfolio. The Nordic life sciences and health tech sectors are thriving, with top entrepreneurial teams translating science into solutions for pressing global challenges like depression and cancer. We’re investing at the forefront of synthetic biology, precision therapies, personalised medicine, predictive diagnostics, and AI-driven innovations,” she adds. “I am extremely pleased to warmly welcome Stina Wallmark to our team. With her strong industry expertise, we’re excited to continue supporting companies that push the boundaries of scaling innovation in health.”
Stina Wallmark sees immense potential in life sciences to address critical global challenges, including the increasing demand for healthcare driven by Europe’s ageing population.
“Life Sciences brings together all the elements on the cutting edge of bio-innovation,” she explains. “It’s not only about advancing healthcare and developing new treatments but also tackling broader issues—breakthroughs in biology can impact food security, clean energy, and beyond.”
Wallmark emphasises that the field needs more than just traditional therapies.
“We need tools to support the entire healthcare workflow, from predictive health diagnostics to smarter, faster therapy innovation,” she says. “Ultimately, I want to help create a better world for my children and future generations by supporting impactful, real-world solutions.”
With offices in Finland and Sweden, Voima Ventures is well-positioned to capitalise on the Nordics’ strengths in Life Sciences.
Jenny Engerfelt, Swedish Partner at Voima Ventures, adds, “We’re seeing remarkable work in Sweden and Denmark, from combating antibiotic resistance to AI-driven diagnostics and drug discovery. These innovations are not only timely but essential in driving the future of healthcare leading to a positive impact for both people and industries. Stina’s strategic insight and connections within the Nordic life sciences ecosystem will enhance Voima Venture’s ability to identify and support high-impact startups in healthcare and biotech.”
Voima Ventures, through its Article 8-compliant Fund III, is dedicated to supporting companies that drive positive environmental, economic, and societal impact.
“We’re at a thrilling juncture where fields like organic chemistry and synthetic biology are intersecting in unprecedented ways,” says Wallmark. “In the near future, diagnostics might even start with something as simple as a smartphone sensor analysing your breath. As science advances, our focus is on investing in teams whose innovations have the potential to make measurable improvements in global health outcomes.”
Click here to read more community news.
Read the orginal article: https://arcticstartup.com/voima-ventures-appoints-stina-wallmark/
